Anti-HV459/ IGHV4-59/ IGHV459 monoclonal antibody

Anti-HV459/ IGHV4-59/ IGHV459 antibody for FACS & in-vivo assay

Target products collectionGo to IGHV4-59/IGHV4-59 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2454-Ab-1/ GM-Tg-hg-MP2454-Ab-2Anti-Human IGHV4-59 monoclonal antibodyHuman
GM-Tg-rg-MP2454-Ab-1/ GM-Tg-rg-MP2454-Ab-2Anti-Rat IGHV4-59 monoclonal antibodyRat
GM-Tg-mg-MP2454-Ab-1/ GM-Tg-mg-MP2454-Ab-2Anti-Mouse IGHV4-59 monoclonal antibodyMouse
GM-Tg-cynog-MP2454-Ab-1/ GM-Tg-cynog-MP2454-Ab-2Anti-Cynomolgus/ Rhesus macaque IGHV4-59 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2454-Ab-1/ GM-Tg-felg-MP2454-Ab-2Anti-Feline IGHV4-59 monoclonal antibodyFeline
GM-Tg-cang-MP2454-Ab-1/ GM-Tg-cang-MP2454-Ab-2Anti-Canine IGHV4-59 monoclonal antibodyCanine
GM-Tg-bovg-MP2454-Ab-1/ GM-Tg-bovg-MP2454-Ab-2Anti-Bovine IGHV4-59 monoclonal antibodyBovine
GM-Tg-equg-MP2454-Ab-1/ GM-Tg-equg-MP2454-Ab-2Anti-Equine IGHV4-59 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2454-Ab-1/ GM-Tg-hg-MP2454-Ab-2; GM-Tg-rg-MP2454-Ab-1/ GM-Tg-rg-MP2454-Ab-2;
GM-Tg-mg-MP2454-Ab-1/ GM-Tg-mg-MP2454-Ab-2; GM-Tg-cynog-MP2454-Ab-1/ GM-Tg-cynog-MP2454-Ab-2;
GM-Tg-felg-MP2454-Ab-1/ GM-Tg-felg-MP2454-Ab-2; GM-Tg-cang-MP2454-Ab-1/ GM-Tg-cang-MP2454-Ab-2;
GM-Tg-bovg-MP2454-Ab-1/ GM-Tg-bovg-MP2454-Ab-2; GM-Tg-equg-MP2454-Ab-1/ GM-Tg-equg-MP2454-Ab-2
Products NameAnti-IGHV4-59 monoclonal antibody
Formatmab
Target NameIGHV4-59
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IGHV4-59 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species HV459/ IGHV4-59/ IGHV459 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2454
    Target NameIGHV4-59
    Gene ID28392
    Gene Symbol and SynonymsIGHV4-59,IGHV459,VH
    Uniprot AccessionP01825
    Uniprot Entry NameHV459_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseCalculus of kidney
    Gene EnsemblENSG00000224373
    Target ClassificationN/A

    The target: IGHV4-59, gene name: IGHV4-59, also named as IGHV459, VH. Predicted to enable antigen binding activity and immunoglobulin receptor binding activity. Predicted to be involved in several processes, including activation of immune response; defense response to other organism; and phagocytosis. Predicted to be located in extracellular region and plasma membrane. Predicted to be part of immunoglobulin complex, circulating. Predicted to be active in external side of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.